Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines

Cancer Letters

Volumn 225, Issue 1, 2005, Pages 61-74

  Yang, Jia Lin ^a   Qu, Xian Jun ^b   Russell, Pamela J ^c   Goldstein, David ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SHANDONG UNIVERSITY   (China)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Colon cancer cell line; Erlotinib; HER1 EGFR inhibitor; Interferon alpha

Indexed keywords

CRYSTAL VIOLET; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; RECOMBINANT ALPHA2A INTERFERON;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; STAINING; STATISTICAL SIGNIFICANCE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; COLONIC NEOPLASMS; GENE EXPRESSION PROFILING; HUMANS; INTERFERON-ALPHA; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; UP-REGULATION;

VIOLA (ANGIOSPERM);

EID: 19544386117     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.11.041     Document Type: Article

References (32)

1. R.M. Elledge, and S.A.W. Fuqua Estrogen and progesterone receptors J.R. Harris M.E. Lippman M. Morrow Osborne, Diseases of the Breast second ed 2000 Lippincott, Williams and Wilkins Philadelphia 471
2. S. Paik, R. Hazan, E.R. Fisher, R.E. Sass, B. Fisher, and C. Redmond Pathological findings from the national surgical adjuvant breast and bowel project: prognostic significance of erbB-2 protein overexpression in primary breast cancer J. Clin. Oncol. 8 1990 103 112
3. R. Supramanian, D.P. Smith, and M.S. Coates Survival from Cancer in New South Wales in 1980-1995 1998 NSW Cancer council Sydney
4. A. Wells Molecules in focus, EGFR receptor Int. J. Biochem. Cell Biol. 31 1999 637 643
5. J.E. Perry, M.E. Grossman, and D.J. Tindall Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line Prostate 35 1998 117 124
6. J.R. Woodburn The epidermal growth factor receptor and its inhibition in cancer therapy Pharmacol. Ther. 82 1999 241 250
7. V. Grunwald, and M. Hidlago Developing inhibitors of the epidermal growth factor receptor for cancer treatment J. Natl Cancer Inst. 95 2003 851 867
8. H. Ge, X. Gong, and C.K. Tang Evidence of high incidence of EGFR VIII expression and coexpression with EGFR in human invasive breast cancer by laser capture micro-dissection and immunohistochemical analysis Int. J. Cancer 98 2002 357 361
9. J.R. Grandis, M.F. Melhem, W.E. Gooding, R. Day, V.A. Holst, and M.M. Wagener Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival J. Natl Cancer Inst. 90 1998 824 832
10. G. Blackledge, and S. Averbuch Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors Br. J. Cancer 90 2004 566 572
11. M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, and J.Y. Douillard Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J. Clin. Oncol. 21 2003 2237 2246
12. M.G. Kris, R.B. Natale, R.S. Herbst, T.J. Lynch Jr, D. Prager, and C.P. Belani Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial J. Am. Med. Assoc. 290 2003 2149 2158
13. V. Grunwald, and M. Hidalgo Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774) Adv. Exp. Med. Biol. 532 2003 235 246
14. D. Soulieres, N.N. Senzer, E.E. Vokes, M. Hidalgo, S.S. Agarwala, and L.L. Siu Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck J. Clin. Oncol. 22 2004 77 85
15. L.B. Saltz, N.J. Meropol, P.J. Loehrer Sr, M.N. Needle, J. Kopit, and R.J. Mayer Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J. Clin. Oncol. 22 2004 1201 1208
16. M. Bos, J. Medelsohn, Y.M. Kim, J. Albanell, D.W. Fry, and J. Baselga PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner Clin. Cancer Res. 3 1997 2099 2106
17. M. Hambek, C. Solbach, H.G. Schuerch, M. Roller, M. Stegmueller, and A. Sterner-Kock Tumor necrosis factor α sensitizes low epidermal growth factor receptor-expressing carcinomas for anti-EGFR therapy Cancer Res. 61 2001 1045 1049
18. V. Grünwald, and M. Hidalgo Developing inhibitors of the epidermal growth factor receptor for cancer treatment J. Natl Cancer Inst. 95 2003 851 867
19. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan Activating Mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 1 11
20. J.-L. Yang, X.-J. Qu, P.J. Russell, and D. Goldstein Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon alpha Gut 53 2004 123 129
21. D. Goldstein, S.M. Bushmeyer, P.L. Witt, V.C. Jordan, and E.C. Borden Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen Cancer Res. 49 1989 2698 2702
22. S.P. Robinson, D. Goldstein, P.L. Witt, E.C. Borden, and V.C. Jordan Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2 Breast Cancer Res. Treat. 5 1990 95 101
23. J.-L. Yang, X.-J. Qu, P.J. Russell, and D. Goldstein Interferon-alpha enhances the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines Am. Assoc. Cancer Res. 2004 4650 (95th Annual Meeting)
24. F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Fontanini, and S. Cuccato Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor Clin. Cancer Res. 7 2001 1459 1465
25. J.H. Chill, R. Nivasch, R. Levy, S. Alback, G. Schreiber, and J. Anglister The human interferon receptor: NMR-based modelling, mapping of the IFN-alpha 2 binding site, and observed ligand-induced tightening Biochemistry 41 2002 3575 3585
26. D.W. Leaman, S. Pisharody, T.W. Flicking, M.A. Commane, J. Schlessinger, and I.M. Kerr Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor Mol. Cell Biol. 16 1996 369 375
27. S.G. Rane, and P. Reddy Janus kinases: components of multiple signaling pathways Oncogene 19 2000 5662 5679
28. E.N. Fish, J. Ghislain, J. Trogadis, and J.K. Stevens Inhibitory effects of alpha-interferon on epidermal growth factor-mediated receptor-dependent events Cancer Res. 53 1993 5148 5157
29. T. Panaretakis, K. Pokrovskaja, M.C. Shoshan, and D. Grander Interferon-α induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax Oncogene 22 2003 4543 4556
30. Q.B. She, D. Solit, A. Basso, and M. Moasser Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akr pathway signaling Clin. Cancer Res. 9 2003 4340 4346
31. R. Bianco, I. Shin, C.A. Ritter, F.M. Yakes, A. Basso, and M. Rosen Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors Oncogene 22 2003 2812 2822
32. T.-C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55